Question

Which of the following statements is NOT true regarding Dopamine in ACLS protocols?

1) First line drug for symptomatic sinus bradycardia
2) given after atropine as a second-line drug for symptomatic bradycardia
3) use for hypotension (systolic blood pressure =/<70 to 100 mm Hg) with signs and symptoms of shock
4) usual infusion rate is 2 to 20 mcg/kg per minute; titrate to patient responses; taper slowly
5) do not mix with sodium bicarbonate

Answer 1

The incorrect statement about Dopamine in ACLS protocols is that it is a first-line drug for symptomatic sinus bradycardia. Dopamine is a second-line medication for bradycardia after atropine and is used for hemodynamic support in shock.

Step-by-step explanation:

The statement among the options provided that is NOT true regarding Dopamine in ACLS protocols is: "First line drug for symptomatic sinus bradycardia." In the Advanced Cardiac Life Support (ACLS) protocols, Dopamine is considered a second-line drug for the treatment of symptomatic bradycardia after atropine has been administered. It is also used for the management of hypotension with signs and symptoms of shock when systolic blood pressure is less than or equal to 70-100 mm Hg, and is not typically the first-line therapy for symptomatic sinus bradycardia. Dopamine infusion rates typically range from 2 to 20 mcg/kg per minute and should be titrated according to the patient's response. It's also important to taper the drug slowly rather than stopping abruptly and to avoid mixing it with sodium bicarbonate due to the potential for drug incompatibility.